EGFR and breast carcinoma: The potential crosstalk of EGFR and NK1R has been described in breast cancer and glioblastoma, showing that NK1R activation affected EGFR phosphorylation and downstream signaling pathways, thus regulating cancer cell proliferation and drug sensitivity.